EyePoint's DURAVYU Misses Primary Endpoint in LUGANO, But Shows Strong Secondary Benefits
EYPT sits 58% above its 52-week low of $9.65.
Summary
EyePoint's DURAVYU failed to meet the primary endpoint of non-inferiority in visual acuity versus aflibercept in the full LUGANO dataset, confounded by a 4% asymmetric cohort with unrelated vision loss. However, an ad hoc analysis excluding that cohort showed non-inferiority (p=0.0096), and key secondary endpoints were strong: 42% reduction in treatment burden (superiority, p<0.0001), 76% supplement-free up to Week 32, and favorable safety. The company plans to file an NDA in 1H 2027 pending LUCIA results in Q4 2026. This is a pivotal binary event for a $1.27B market cap company with a cash-burning pipeline; the mixed results create significant uncertainty about regulatory approval and commercial positioning. The stock is likely to react sharply to the primary endpoint miss despite the secondary positives. Conference call today at 8:00 a.m. EDT will provide management's interpretation and next steps.
At the time of this announcement, EYPT was trading at $15.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.65 to $19.11. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.